Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.36

-0.31 (-0.98%)

06:35
11/06/18
11/06
06:35
11/06/18
06:35

Mylan target raised to $39 on 'comforting' Q3 results at Mizuho

Mylan reported "comforting" Q3 results with $300M in high margin new product sales and reiterated its 2018 guidance, Mizuho analyst Irina Koffler tells investors in a post-earnings research note. The analyst raised her price target for the shares to $39 from $37 and reiterates a Neutral rating on the name.

  • 13

    Nov

MYL Mylan
$31.36

-0.31 (-0.98%)

11/06/18
JPMS
11/06/18
NO CHANGE
Target $45
JPMS
Overweight
Mylan Q3 better than feared, recent selloff overdone, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's Q3 results as "better than feared" and a "step in the right direction." While the company's North American business remains under pressure, year-over-year erosion for the business improved from Q2, overall gross margins showed solid year-over-year improvement and Mylan maintained its annual guidance, Schott tells investors in a post-earnings research note. The analyst views the recent weakness in the shares as overdone and keeps an Overweight rating on the name with a $45 price target. Looking beyond near-term challenges, Mylan is one of the better-positioned players in the space with a number of longer-term growth drivers in place, including biosimilars and the pending generic Advair approval, says Schott.
11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
10/12/18
WELS
10/12/18
NO CHANGE
WELS
Market Perform
Merck returning Lantus biosimilar rights negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris sees a negative read-through for Mylan regarding yesterday's news of Merck Sharp & Dohme Research returning the rights to biosimilar Lantus to Samsung Bioepis. While some view this as a positive, as there will likely be one fewer competitor in the market if Mylan-Biocon make it to the U.S. market, that is a "simplistic and optimistic" take, Maris tells investors in a research note. The more important factor to consider is the "why" Merck dropped out, rather than the number of competitors, the analyst writes. He believes Merck returned the rights to Samsung Bioepis due to the deteriorating pricing environment and pricing outlook for insulin and Lantus biosimilars. Lilly's and Sanofi's manufacturing capacity, along with aggressive discounting, has created a "severe pricing environment," Maris contends. He believes that if Samsung Bioepis and Merck can't make the economics work, than one should be skeptical of Mylan and Biocon having substantial success. Maris has a Market Perform rating on Mylan shares.

TODAY'S FREE FLY STORIES

OTEX

OpenText

$33.20

0.32 (0.97%)

09:10
11/19/18
11/19
09:10
11/19/18
09:10
Hot Stocks
Sun Chemical selects OpenText to improve customer service »

OpenText announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFIN

BankFinancial

$14.55

0.17 (1.18%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
BankFinancial extends, expands share repurchase program »

BankFinancial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMHC

Houghton Mifflin

$8.84

-0.12 (-1.34%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
Houghton Mifflin: Texas SBE approves new K-8 reading programs »

Houghton Mifflin Harcourt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Breaking Earnings news story on Leju »

Leju sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Leju reports Q3 adj. EPS 8c, one estimate (2c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

GLYC

GlycoMimetics

$11.94

0.34 (2.93%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
GlycoMimetics enrolls first patient in Phase 3 clinical trial of uproleselan »

GlycoMimetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

, CVS

CVS Health

$79.33

-0.48 (-0.60%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
Florida AG amends opioid lawsuit complaint to include Walgreens, CVS »

Attorney General Pam…

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

INSY

Insys Therapeutics

$7.08

-0.13 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

DISH

Dish

$32.85

-0.25 (-0.76%)

, CTL

CenturyLink

$19.16

0.19 (1.00%)

09:02
11/19/18
11/19
09:02
11/19/18
09:02
Hot Stocks
Dish names Atilla Tinic as Chief Information Officer »

DISH (DISH) announced…

DISH

Dish

$32.85

-0.25 (-0.76%)

CTL

CenturyLink

$19.16

0.19 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

, MSI

Motorola Solutions

$129.97

0.72 (0.56%)

09:01
11/19/18
11/19
09:01
11/19/18
09:01
Hot Stocks
Aviat Networks selected by Motorola Solutions for Florida's P25 network »

Aviat Networks (AVNW)…

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 18

    Dec

  • 19

    Dec

YETI

Yeti

$16.99

0.1 (0.59%)

09:00
11/19/18
11/19
09:00
11/19/18
09:00
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GE

General Electric

$8.04

-0.135 (-1.65%)

08:57
11/19/18
11/19
08:57
11/19/18
08:57
Hot Stocks
GE announces new leadership in Power reorganization »

GE recently announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.04

-0.135 (-1.65%)

, FB

Facebook

$139.55

-4.31 (-3.00%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Options
Notable open interest changes for November 19th »

Friday's total…

GE

General Electric

$8.04

-0.135 (-1.65%)

FB

Facebook

$139.55

-4.31 (-3.00%)

NVDA

Nvidia

$164.38

-38.27 (-18.88%)

JD

JD.com

$23.04

-1.18 (-4.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 10

    Dec

BKI

Black Knight

$49.77

0.87 (1.78%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Conference/Events
Black Knight to host Investor Day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 03

    Dec

ENR

Energizer

$49.91

-1.53 (-2.97%)

, SPB

Spectrum Brands

$59.36

0.87 (1.49%)

08:54
11/19/18
11/19
08:54
11/19/18
08:54
Recommendations
Energizer, Spectrum Brands analyst commentary  »

Energizer price target…

ENR

Energizer

$49.91

-1.53 (-2.97%)

SPB

Spectrum Brands

$59.36

0.87 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

, RAD

Rite Aid

$1.22

0.01 (0.83%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Amazon.com, Rite Aid, Walgreens Boots Alliance, CVS Health analyst commentary  »

Jefferies uncovers signs…

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

RAD

Rite Aid

$1.22

0.01 (0.83%)

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 02

    Dec

  • 04

    Dec

WP

Worldpay

$82.05

-0.62 (-0.75%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Worldpay analyst commentary  »

Worldpay elevated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

08:50
11/19/18
11/19
08:50
11/19/18
08:50
General news
U.S. equities are back under pressure »

U.S. equities are back…

08:49
11/19/18
11/19
08:49
11/19/18
08:49
Conference/Events
Jefferies defense analysts to hold an analyst/industry conference call »

Defense Analysts provide…

RNG

RingCentral

$76.41

-0.54 (-0.70%)

08:49
11/19/18
11/19
08:49
11/19/18
08:49
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$31.29

-0.1 (-0.32%)

08:47
11/19/18
11/19
08:47
11/19/18
08:47
Recommendations
Masco analyst commentary  »

Masco portfolio offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCON

TRACON Pharmaceuticals

$1.30

0.005 (0.39%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Hot Stocks
TRACON Pharmaceuticals TRC102, Temodar trial does not meet primary endpoint »

TRACON Pharmaceuticals …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFR

Cullen/Frost

$101.35

0.11 (0.11%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Conference/Events
Cullen/Frost has a conference call hosted by SunTrust »

SunTrust Analyst Demba…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PINC

Premier

$39.60

-0.26 (-0.65%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Recommendations
Premier analyst commentary  »

Baird sees Premier shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$66.49

0.68 (1.03%)

, ACRX

AcelRx

$2.92

0.07 (2.46%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

BAX

Baxter

$66.49

0.68 (1.03%)

ACRX

AcelRx

$2.92

0.07 (2.46%)

XOP

SPDR Oil Exploration and Production Fund

$34.75

-0.055 (-0.16%)

HEAR

Turtle Beach

$15.17

0.15 (1.00%)

NWL

Newell Brands

$21.69

0.32 (1.50%)

EBIX

Ebix

$51.54

1.83 (3.68%)

CNAT

Conatus

$4.82

0.16 (3.43%)

TRVN

Trevena

$0.64

-0.0056 (-0.87%)

EMR

Emerson

$69.68

0.86 (1.25%)

HUYA

Huya

$17.68

-0.45 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 11

    Dec

BB

BlackBerry

$8.97

0.12 (1.36%)

08:43
11/19/18
11/19
08:43
11/19/18
08:43
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.